De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
BioNTech Beheer
Beheer criteriumcontroles 4/4
De CEO BioNTech's is Ugur Sahin, benoemd in Jan2008, heeft een ambtstermijn van 16.75 jaar. De totale jaarlijkse vergoeding van { bedraagt € 3.06M, bestaande uit 22.9% salaris en 77.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 17.37% van de aandelen van het bedrijf, ter waarde $ 4.90B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 4.5 jaar.
Belangrijke informatie
Ugur Sahin
Algemeen directeur
€3.1m
Totale compensatie
| Percentage CEO-salaris | 22.9% |
| Dienstverband CEO | 16.8yrs |
| Eigendom CEO | 17.4% |
| Management gemiddelde ambtstermijn | 4yrs |
| Gemiddelde ambtstermijn bestuur | 4.5yrs |
Recente managementupdates
Recent updates
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€504m |
| Mar 31 2024 | n/a | n/a | €113m |
| Dec 31 2023 | €3m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
| Sep 30 2019 | n/a | n/a | -€122m |
| Jun 30 2019 | n/a | n/a | -€116m |
| Mar 31 2019 | n/a | n/a | -€77m |
| Dec 31 2018 | €653k | €210k | -€48m |
Compensatie versus markt: De totale vergoeding ($USD 3.38M ) Ugur } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).
Compensatie versus inkomsten: De vergoeding van Ugur is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Ugur Sahin (59 yo)
16.8yrs
Tenure
€3,056,000
Compensatie
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 16.8yrs | €3.06m | 17.37% € 5.1b | |
| Co-Founder | 6.8yrs | €814.00k | 0.38% € 112.0m | |
| CFO & Member of Management Board | 3.3yrs | €1.32m | 0.00068% € 198.4k | |
| MD, COO & Member of Management Board | 10.8yrs | €821.00k | 0.32% € 92.6m | |
| Chief Strategy Officer | 4.8yrs | €1.41m | 0.0062% € 1.8m | |
| Chief Legal & Business Officer & Member of the Management Board | 1.1yrs | €848.00k | geen gegevens | |
| Executive Officer | less than a year | €133.00k | 0.34% € 100.0m | |
| Senior Vice President of Corporate Development & Strategy | less than a year | geen gegevens | geen gegevens | |
| Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Operations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Global R&D Digital | no data | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BNTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Supervisory Board Member | 2.3yrs | €90.00k | 0.00017% € 49.6k | |
| Independent Deputy Chairman Supervisory Board | 6.8yrs | €114.00k | geen gegevens | |
| Independent Supervisory Board Member | 16.8yrs | €80.00k | geen gegevens | |
| Independent Supervisory Board Chairman | 16.8yrs | €226.00k | 0.14% € 40.8m | |
| Member of Supervisory Board | 1.4yrs | €46.00k | geen gegevens | |
| Supervisory Board Member | 2.3yrs | €105.00k | 0.00010% € 29.2k |
4.5yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BNTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).